NYSE · WST
Healthcare · Medical - Instruments & Supplies
$366.00
Up+$2.73 (+0.75%)
Updated Oct 10, 2026, 5:08 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · WST
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
WST closed at $366.00 after 21 trading sessions, up 5.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $363.31 | $370.20 | $362.175 | $366.00 | 480.22K |
| Oct 8, 2026 | $365.65 | $367.25 | $359.4886 | $363.27 | 461.7K |
| Oct 7, 2026 | $371.66 | $374.79 | $365.345 | $366.48 | 438.04K |
| Oct 6, 2026 | $379.02 | $381.16 | $367.635 | $372.64 | 401.4K |
| Oct 5, 2026 | $364.69 | $377.06 | $363.16 | $376.76 | 682.77K |
| Oct 2, 2026 | $364.74 | $368.8538 | $363.26 | $364.98 | 473.02K |
| Oct 1, 2026 | $367.52 | $370.25 | $363.115 | $365.01 | 670.87K |
| Sep 30, 2026 | $375.35 | $376.19 | $370.13 | $370.76 | 471.18K |
| Sep 29, 2026 | $375.51 | $377.78 | $370.801 | $376.63 | 560.12K |
| Sep 28, 2026 | $366.55 | $378.47 | $366.55 | $375.65 | 567.56K |
| Sep 25, 2026 | $372.01 | $372.135 | $368.45 | $370.44 | 434.01K |
| Sep 24, 2026 | $378.67 | $382.71 | $370.71 | $373.60 | 715.93K |
| Sep 23, 2026 | $370.93 | $376.06 | $368.20 | $375.87 | 876.99K |
| Sep 22, 2026 | $367.42 | $375.395 | $365.255 | $371.09 | 734.7K |
| Sep 21, 2026 | $363.78 | $366.115 | $361.05 | $361.78 | 506.8K |
| Sep 18, 2026 | $366.59 | $366.86 | $359.52 | $362.31 | 1.46M |
| Sep 17, 2026 | $366.20 | $368.795 | $363.14 | $366.60 | 474.06K |
| Sep 16, 2026 | $363.11 | $367.33 | $361.0616 | $362.01 | 621.05K |
| Sep 15, 2026 | $355.02 | $370.67 | $354.65 | $365.00 | 981.89K |
| Sep 14, 2026 | $349.94 | $356.61 | $345.15 | $355.20 | 625.56K |
| Sep 11, 2026 | $343.87 | $351.96 | $341.675 | $346.23 | 541.79K |
The latest Smart Investors Daily articles mentioning WST.
Company
Market Activity
Research & News
WST research
Company profile and research snapshot.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 22, 2026 | Morgan Stanley | Overweight | — |
| Sep 9, 2026 | UBS | Buy | — |
| Aug 3, 2026 | Citigroup | Buy | — |
| Jul 27, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.
Yahoo · Sep 28, 2026
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
Yahoo · Sep 25, 2026
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.
Yahoo · Sep 23, 2026
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WST.
